Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinlianhua Diwan is a Traditional Chinese Medicine (TCM) product developed and manufactured by Jiangsu Jiuxu Pharmaceutical. It is formulated as oral drop pills containing extracts from the herb *Trollius chinensis* Bunge (Golden Lotus Flower). The drug is primarily indicated for the treatment of upper respiratory tract conditions, including acute pharyngitis and tonsillitis, characterized by symptoms such as sore throat and swelling. Pharmacologically, it is recognized for its heat-clearing and detoxifying properties, which translate to anti-inflammatory and antimicrobial activities in clinical applications. It is an approved product in China and is part of Jiangsu Jiuxu's core TCM portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinlianhua Diwan.